Evidence map›Paper›PMID 36932247›Full record

ArticleNature medicine2023

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.

Sham Mailankody, Jeffrey V Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz and 8 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Early data indicate safety of allogeneic CAR T cells.Nature reviews. Clinical oncology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Sham MailankodyMyeloma Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mailanks@mskcc.org.ORCID http://orcid.org/0000-0002-2815-9561
Jeffrey V MatousColorado Blood Cancer Institute, Denver, CO, USA.
Saurabh ChhabraDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0001-9117-8696
Michaela LiedtkeDivision of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA.
Surbhi SidanaDivision of Bone Marrow Transplantation and Cellular Therapy, Stanford University Hospital, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3288-7614
Olalekan O OluwoleVanderbilt University Medical Center, Nashville, TN, USA.
Shahbaz MalikBone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX, USA.
Rajneesh NathBanner MD Anderson Cancer Center, Gilbert, AZ, USA.
Faiz AnwerTaussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Jose Carlos CruzTexas Transplant Institute, San Antonio, TX, USA.
Myo HtutDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, USA.
Erin E KarskiAllogene Therapeutics, South San Francisco, CA, USA.
Wade LovelaceAllogene Therapeutics, South San Francisco, CA, USA.
Myles DillonAllogene Therapeutics, South San Francisco, CA, USA.
Eric ButzAllogene Therapeutics, South San Francisco, CA, USA.
Wendy YingAllogene Therapeutics, South San Francisco, CA, USA.
Arun BalakumaranAllogene Therapeutics, South San Francisco, CA, USA.
Shaji K KumarMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36932247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.